Opus Genetics 경영진

경영진 기준 점검 3/4

Opus Genetics CEO는 George Magrath, Nov2023 에 임명되었습니다 의 임기는 2.67 년입니다. 총 연간 보상은 $1.49M, 40% 급여 및 60% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $3.42M 가치에 해당하는 회사 주식의 1.03% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.5 년과 4.2 년입니다.

핵심 정보

George Magrath

최고경영자

US$1.5m

총 보수

CEO 급여 비율	40.04%
CEO 재임 기간	2.7yrs
CEO 지분 보유율	1.0%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	4.2yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Feb 07

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

Opus Genetics, Inc. ( NASDAQ:IRD ) shareholders have had their patience rewarded with a 43% share price jump in the...

분석 기사 • Dec 11

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 27% in...

분석 기사 • Sep 09

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 31% in...

분석 기사 • Jul 11

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc.'s ( NASDAQ:IRD ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right now...

분석 기사 • May 19

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

Investors in Opus Genetics, Inc. ( NASDAQ:IRD ) had a good week, as its shares rose 7.4% to close at US$1.02 following...

분석 기사 • Apr 09

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Opus Genetics, Inc. ( NASDAQ:IRD ) share price has dived 25% in the last...

분석 기사 • Aug 19

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Celebrations may be in order for Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders, with the analysts delivering a...

분석 기사 • Jul 24

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders have had their patience rewarded with a 30% share price jump in the...

분석 기사 • Jul 12

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

분석 기사 • May 02

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) share price has dived 26% in the last...

분석 기사 • Mar 15

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders that were waiting for something to happen have been dealt a blow...

CEO 보수 분석

George Magrath의 보수는 Opus Genetics의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2026	n/a	n/a	-US$107m
Dec 31 2025	US$1m	US$598k	-US$50m
Sep 30 2025	n/a	n/a	-US$68m
Jun 30 2025	n/a	n/a	-US$58m
Mar 31 2025	n/a	n/a	-US$59m
Dec 31 2024	US$889k	US$575k	-US$58m
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$96k	-US$10m

보상 대 시장: George의 총 보수(USD1.49M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.47M)보다 낮습니다.

보상과 수익: George의 보상은 회사가 적자임에도 증가했습니다.

CEO

George Magrath (41 yo)

2.7yrs

재임 기간

US$1,493,383

보수

Dr. George Magrath, MD, MBA, MS, serves as Chief Executive Officer & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment...

리더십 팀

이름	직위	재임 기간	보수	지분
George Magrath	CEO & Director	2.7yrs	US$1.49m	1.03% $ 3.4m
Benjamin Yerxa	President & Director	1.8yrs	데이터 없음	0.87% $ 2.9m
Joseph Schachle	Chief Operating Officer	2.7yrs	US$718.41k	0.027% $ 90.9k
Ashwath Jayagopal	Chief Scientific & Development Officer	2.4yrs	US$764.85k	0.070% $ 233.5k
Robert Gagnon	CFO & Principal Accounting Officer	less than a year	데이터 없음	0.73% $ 2.4m
Chris Ernst	Chief Technology Officer	no data	데이터 없음	데이터 없음
Jenny Kobin	Investor Relations Officer	no data	데이터 없음	데이터 없음
Bernhard Hoffmann	Senior Vice President of Corporate Development & Secretary	no data	US$789.92k	0.14% $ 478.8k
Amy Zaremba Rabourn	Head of Financial Quality Assurance	no data	US$789.92k	0.057% $ 188.4k
Bindu Manne	Head of Market Development & Commercialization	4.5yrs	데이터 없음	데이터 없음
Sally Tucker	Chief Medical Officer & Senior Vice President of Clinical Development	no data	데이터 없음	데이터 없음
Sarah Tuller	Chief Regulatory Officer	no data	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

52yo

평균 나이

경험이 풍부한 관리: IRD의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.5 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
George Magrath	CEO & Director	2.7yrs	US$1.49m	1.03% $ 3.4m
Benjamin Yerxa	President & Director	1.8yrs	데이터 없음	0.87% $ 2.9m
James S. Manuso	Independent Director	5.7yrs	US$188.92k	0.36% $ 1.2m
Adrienne Graves	Independent Director	1.8yrs	US$171.44k	0.13% $ 419.8k
David Boyer	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Richard Rodgers	Independent Director	5.7yrs	US$189.45k	0.39% $ 1.3m
Susan Benton	Independent Director	5.7yrs	US$180.14k	0.27% $ 893.5k
Cameron Gallagher	Independent Chairman	5.7yrs	US$295.97k	2.43% $ 8.0m
Sean Ainsworth	Lead Independent Director	5.7yrs	US$210.14k	0.37% $ 1.2m
Jean Bennett	Director	1.8yrs	US$168.50k	0.29% $ 955.0k
Arshad Khanani	Member of Medical Advisory Board	2.3yrs	데이터 없음	데이터 없음
Mark Pennesi	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

59.5yo

평균 나이

경험이 풍부한 이사회: IRD의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.2 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/07/07 14:49
종가	2026/07/07 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Opus Genetics, Inc.는 18명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
James Molloy	Alliance Global Partners
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets

Opus Genetics 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

CEO & Director notifies of intention to sell stock

High number of new directors

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc., Annual General Meeting, Apr 20, 2026

Independent Chairman recently bought US$324k worth of stock

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Recent updates

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for Opgx-Lca5 in Lca5-Associated Inherited Retinal Disease

New major risk - Shareholder dilution

Consensus EPS estimates fall by 77%

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Opus Genetics Completes Enrollment In Cohort 1 Of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces Fda Acceptance of Opgx-Lca5 into Rare Disease Evidence Principles (Rdep) Program

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc. announced that it expects to receive $159.928 million in funding from Oberland Capital Management LLC

High number of new directors

Consensus EPS estimates fall by 19%, revenue upgraded

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc., Annual General Meeting, Apr 20, 2026

Price target increased by 7.5% to US$9.50

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 14% to US$8.83

Opus Genetics, Inc. Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics, Inc. Announces Fda Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. announced that it has received $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

New minor risk - Share price stability

Opus Genetics, Inc. Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis Pigmentosa

Independent Chairman recently bought US$324k worth of stock

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Consensus EPS estimates fall by 16%, revenue upgraded

Third quarter 2025 earnings: EPS misses analyst expectations

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $23 million.

Price target increased by 13% to US$6.80

New major risk - Revenue and earnings growth

Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in September

Opus Genetics, Inc. announced that it has received $3.5 million in funding

Consensus revenue estimates decrease by 18%, EPS upgraded

Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate OPGx-Best1

New major risk - Financial position

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Consensus revenue estimates increase by 16%

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Price target decreased by 13% to US$9.25

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Consensus revenue estimates increase by 34%

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

New major risk - Shareholder dilution

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

CEO & Director recently bought US$98k worth of stock

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded